Who is sponsoring NCT04351854?

NCT04351854 is sponsored by University of Cologne.

What drugs are being tested in NCT04351854?

Interventions in NCT04351854: Retrospective data collection.

What condition does NCT04351854 study?

NCT04351854 studies Corona Virus Infection, SARS-CoV 2.

Is NCT04351854 still recruiting?

NCT04351854 is currently completed. Last updated 25 May 2022.

Last reviewed 2022-05-25 · How we verify

NCT04351854: ReCovER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room

Completed Last updated 25 May 2022

What this trial tests

trial testing Retrospective data collection in Corona Virus Infection in 500 participants. Completed in 31 January 2022.

Timeline

20 April 2020

Primary endpoint
31 January 2022

31 January 2022

Quick facts

Lead sponsor	University of Cologne
Status	Completed
Study type	OBSERVATIONAL
Enrollment	500
Start date	20 April 2020
Primary completion	31 January 2022
Estimated completion	31 January 2022
Sites	1 location across Germany

Drugs / interventions tested

Retrospective data collection

Conditions studied

Corona Virus Infection — all drugs for Corona Virus Infection →
SARS-CoV 2 — all drugs for SARS-CoV 2 →

Sponsor

University of Cologne

Who can join

Eligibility, any sex, with Corona Virus Infection or SARS-CoV 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED. The course of the disease prior to admission as well as the momentary health status at presentation to the ED are of interest because they influence risk stratification and decision-making of treating physicians. The ratio of patients with mild or moderate to severe symptoms will help to calculate the need for hospital beds including beds on Intensive Care Units (ICU) and Intermediate Care Units (IMC), as well as the need for other hospital resources.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Which parameters support disposition decision in suspected COVID-19 cases in the emergency department (ED): a German clinical cohort study.
Möckel M, Stegemann MS, Burst V, Kümpers P, et al · · 2021 · cited 7× · PMID 33789854 · DOI 10.1136/bmjopen-2020-044853
[University emergency departments in the corona pandemic-Results from the ReCovER registry].
Suárez V, Koehler FC, Hackl MJ, Möckel M, et al · · 2022 · cited 1× · PMID 34468772 · DOI 10.1007/s00063-021-00859-4
COVID-19 in the Emergency Department (ED): Patient Characteristics, Outcome and Parameters for Hospitalization
Möckel M, Stegemann MS, Burst V, Kümpers P, et al · · 2020 · DOI 10.2139/ssrn.3684466

Verify or expand the search:

Other trials of Retrospective data collection

Trials testing the same drug.

NCT07344480 — Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM) · recruiting
NCT05271981 — Fertility After Uterine Artery Embolization · completed
NCT04496544 — Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel-coated Devices (SAFE-PAD Study) · completed
NCT04797091 — Kidney in Coronavirus Disease 2019 Registry · completed
NCT03420066 — The NEXUS™ Compassionate Use Data Collection Study · completed

Other recruiting trials for Corona Virus Infection

Currently open trials in the same condition.

NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT05684549 — Coronavirus Infection (COVID-19) and Radical Surgery in Patients With Early-stage Lung Cancer · active not recruiting
NCT04382846 — Novel Regimens in COVID-19 Treatment · Phase 3 · recruiting
NCT04371315 — Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting

Other University of Cologne trials

Trials by the same sponsor.

NCT07280585 — STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease · Phase 3 · recruiting
NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
NCT06781710 — Analysis of the Epidemiology, Clinical Presentation and Therapy as Well as Therapy-associated Risk of Demyelination Synd · recruiting
NCT05969431 — Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study · recruiting
NCT05876221 — Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04351854 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Cologne
Last refreshed: 25 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04351854.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing